{
    "Variants Include": [
        {
            "Gene": "LRRK2",
            "variants": [
                {
                    "HGVS": "NM_198578.4:c.6059T>C",
                    "cDNA Change": {
                        "transcript": "NM_198578.4",
                        "ref": "T",
                        "alt": "C",
                        "position": "6059"
                    },
                    "Protein Change": {
                        "ref": "I",
                        "alt": "T",
                        "position": "2020"
                    },
                    "Description in input context": "I2020T"
                },
                {
                    "HGVS": "NM_198578.4:c.6055G>A",
                    "cDNA Change": {
                        "transcript": "NM_198578.4",
                        "ref": "G",
                        "alt": "A",
                        "position": "6055"
                    },
                    "Protein Change": {
                        "ref": "G",
                        "alt": "S",
                        "position": "2019"
                    },
                    "Description in input context": "G2019S"
                }
            ]
        }
    ],
    "Described Disease": {
        "Described Disease": "Parkinson's Disease",
        "MONDO": "MONDO:0005180"
    },
    "Experiment Method": [
        {
            "Assay Method": "TR-FRET Competitive Binding Assay",
            "Material used": {
                "Material Source": "Recombinant Protein",
                "Material Name": "N-terminal GST-tagged LRRK2",
                "Description": "N-terminal GST-tagged LRRK2 (amino acids 970-2527) wild-type, G2019S, and I2020T were from Invitrogen Corporation."
            },
            "Readout type": "Quantitative",
            "Readout description": [
                {
                    "Variant": "NM_198578.4:c.6059T>C",
                    "Conclusion": "N.D.",
                    "Molecular Effect": "N.D.",
                    "Result Description": "I2020T has approximately 9-fold higher ATP affinity compared to wild-type LRRK2."
                },
                {
                    "Variant": "NM_198578.4:c.6055G>A",
                    "Conclusion": "N.D.",
                    "Molecular Effect": "N.D.",
                    "Result Description": "G2019S has about 2-fold lower ATP affinity compared to wild-type LRRK2."
                }
            ],
            "Biological replicates": {
                "Biological replicates": "N.D.",
                "Description": "N.D."
            },
            "Technical replicates": {
                "Technical replicates": "Yes",
                "Description": "All binding assays were performed in 384-well low volume plates with specified conditions."
            },
            "Basic positive control": {
                "Basic positive control": "N.D.",
                "Description": "N.D."
            },
            "Basic negative control": {
                "Basic negative control": "N.D.",
                "Description": "N.D."
            },
            "Validation controls P/LP": {
                "Validation controls P/LP": "N.D.",
                "Counts": "N.D."
            },
            "Validation controls B/LB": {
                "Validation controls B/LB": "N.D.",
                "Counts": "N.D."
            },
            "Statistical analysis method": {
                "Statistical analysis method": "Curve fitting and data analysis were performed with GraphPad Prism software."
            },
            "Threshold for normal readout": {
                "Threshold for normal readout": "ATP affinity similar to wild-type LRRK2 (approximately 39 µM).",
                "Source": "Custom"
            },
            "Threshold for abnormal readout": {
                "Threshold for abnormal readout": "ATP affinity significantly different from wild-type LRRK2 (e.g., <10 µM or >70 µM).",
                "Source": "Custom"
            },
            "Approved assay": {
                "Approved assay": "Yes"
            }
        },
        {
            "Assay Method": "Radiometric Kinase Activity Assay",
            "Material used": {
                "Material Source": "Recombinant Protein",
                "Material Name": "N-terminal GST-tagged LRRK2",
                "Description": "N-terminal GST-tagged LRRK2 (amino acids 970-2527) wild-type, G2019S, and I2020T were from Invitrogen Corporation."
            },
            "Readout type": "Quantitative",
            "Readout description": [
                {
                    "Variant": "NM_198578.4:c.6059T>C",
                    "Conclusion": "Abnormal",
                    "Molecular Effect": "partial loss-of-function",
                    "Result Description": "I2020T showed a 7-fold lower ATP Km,app (7.5 µM) and 3-fold lower Vmax compared to wild-type LRRK2."
                },
                {
                    "Variant": "NM_198578.4:c.6055G>A",
                    "Conclusion": "Abnormal",
                    "Molecular Effect": "gain-of-function",
                    "Result Description": "G2019S showed a 3-fold higher ATP Km,app (169 µM) and 3-fold higher specific activity compared to wild-type LRRK2."
                }
            ],
            "Biological replicates": {
                "Biological replicates": "N.D.",
                "Description": "N.D."
            },
            "Technical replicates": {
                "Technical replicates": "Yes",
                "Description": "Kinase reactions were performed in duplicate."
            },
            "Basic positive control": {
                "Basic positive control": "N.D.",
                "Description": "N.D."
            },
            "Basic negative control": {
                "Basic negative control": "N.D.",
                "Description": "N.D."
            },
            "Validation controls P/LP": {
                "Validation controls P/LP": "N.D.",
                "Counts": "N.D."
            },
            "Validation controls B/LB": {
                "Validation controls B/LB": "N.D.",
                "Counts": "N.D."
            },
            "Statistical analysis method": {
                "Statistical analysis method": "Michaelis-Menten equation was fit to the data using GraphPad Prism software."
            },
            "Threshold for normal readout": {
                "Threshold for normal readout": "ATP Km,app similar to wild-type LRRK2 (approximately 51 µM).",
                "Source": "Custom"
            },
            "Threshold for abnormal readout": {
                "Threshold for abnormal readout": "ATP Km,app significantly different from wild-type LRRK2 (e.g., <10 µM or >150 µM).",
                "Source": "Custom"
            },
            "Approved assay": {
                "Approved assay": "Yes"
            }
        },
        {
            "Assay Method": "TR-FRET Kinase Activity Assay",
            "Material used": {
                "Material Source": "Recombinant Protein",
                "Material Name": "N-terminal GST-tagged LRRK2",
                "Description": "N-terminal GST-tagged LRRK2 (amino acids 970-2527) wild-type, G2019S, and I2020T were from Invitrogen Corporation."
            },
            "Readout type": "Quantitative",
            "Readout description": [
                {
                    "Variant": "NM_198578.4:c.6059T>C",
                    "Conclusion": "Abnormal",
                    "Molecular Effect": "partial loss-of-function",
                    "Result Description": "I2020T was incompletely inhibited by sunitinib at 1 mM ATP with an IC50 value of at least 5 µM, indicating resistance to ATP-competitive inhibitors."
                },
                {
                    "Variant": "NM_198578.4:c.6055G>A",
                    "Conclusion": "Abnormal",
                    "Molecular Effect": "gain-of-function",
                    "Result Description": "G2019S was modestly more sensitive to sunitinib inhibition at 1 mM ATP with an IC50 value of 230 nM compared to wild-type LRRK2."
                }
            ],
            "Biological replicates": {
                "Biological replicates": "N.D.",
                "Description": "N.D."
            },
            "Technical replicates": {
                "Technical replicates": "Yes",
                "Description": "All assays were performed using either three or four replicates for each data point."
            },
            "Basic positive control": {
                "Basic positive control": "N.D.",
                "Description": "N.D."
            },
            "Basic negative control": {
                "Basic negative control": "N.D.",
                "Description": "N.D."
            },
            "Validation controls P/LP": {
                "Validation controls P/LP": "N.D.",
                "Counts": "N.D."
            },
            "Validation controls B/LB": {
                "Validation controls B/LB": "N.D.",
                "Counts": "N.D."
            },
            "Statistical analysis method": {
                "Statistical analysis method": "Curve fitting and data analysis were performed with GraphPad Prism software."
            },
            "Threshold for normal readout": {
                "Threshold for normal readout": "IC50 value for sunitinib similar to wild-type LRRK2 (approximately 370 nM at 1 mM ATP).",
                "Source": "Custom"
            },
            "Threshold for abnormal readout": {
                "Threshold for abnormal readout": "IC50 value for sunitinib significantly different from wild-type LRRK2 (e.g., >1 µM or <250 nM at 1 mM ATP).",
                "Source": "Custom"
            },
            "Approved assay": {
                "Approved assay": "Yes"
            }
        }
    ]
}